

Naiyer A Rizvi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2938313/publications.pdf>

Version: 2024-02-01

79
papers

33,241
citations

117453

34
h-index

82410

72
g-index

80
all docs

80
docs citations

80
times ranked

33514
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100310.	0.6	1
2	Baseline peripheral T-cell composition in relation to radiographic phenotypes of immune-related pneumonitis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2545-2545.	0.8	0
3	A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study. <i>Clinical Cancer Research</i> , 2021, 27, 1631-1640.	3.2	70
4	Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response. <i>Cancer Discovery</i> , 2021, 11, 282-292.	7.7	132
5	Network meta-analysis (NMA) of immuno-oncology (IO) monotherapy as first-line (1L) treatments (txs) for advanced non-small cell lung cancer (NSCLC) with PD-L1 expression $\geq 50\%$.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21091-e21091.	0.8	0
6	Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) $\geq 50\%$: EMPOWER-Lung 1 subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9085-9085.	0.8	6
7	Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC). <i>Clinical Lung Cancer</i> , 2021, 22, 301-312.e8.	1.1	10
8	Abstract CT163: CD73 inhibitor oleclumab plus osimertinib for advanced EGFRm NSCLC: First report of a Phase 1b/2 study. <i>Cancer Research</i> , 2021, 81, CT163-CT163.	0.4	8
9	Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study. <i>Lung Cancer</i> , 2020, 147, 137-142.	0.9	37
10	Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 5358-5367.	3.2	53
11	STK11/LKB1 mutations in metastatic NSCLC: Prognostic value in the real world. <i>PLoS ONE</i> , 2020, 15, e0238358.	1.1	44
12	Safety and Clinical Activity of MEDI1873, a Novel G1TR Agonist, in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 6196-6203.	3.2	35
13	Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 786-795.	5.1	419
14	Characteristics and outcomes of lung cancer in solid organ transplant recipients. <i>Lung Cancer</i> , 2020, 146, 297-302.	0.9	8
15	Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 661.	3.4	446
16	Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e47-e57.	1.8	30
17	A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS9627-TPS9627.	0.8	2
18	SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9623-9623.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1390-1399.	0.5	40
20	Management Strategies for Early-Onset Pulmonary Events Associated with Brigatinib. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1547-1555.	0.5	20
21	Treatment Outcomes of Immune-Related Cutaneous Adverse Events. <i>Journal of Clinical Oncology</i> , 2019, 37, 2746-2758.	0.8	160
22	Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2518-2527.	0.8	811
23	Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. <i>Nature Medicine</i> , 2019, 25, 1715-1720.	15.2	194
24	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	9.4	2,702
25	Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9016-9016.	0.8	20
26	Patient-reported outcomes (PROs) with first-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic NSCLC: Results from MYSTIC.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9048-9048.	0.8	2
27	Combining chemotherapy with PD-1 blockade in NSCLC. , 2018, 186, 130-137.		97
28	Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 853-861.e4.	7.7	725
29	Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy. <i>BMC Cancer</i> , 2018, 18, 225.	1.1	28
30	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 521-536.	5.1	486
31	Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. <i>Science</i> , 2018, 359, 582-587.	6.0	834
32	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1818-1831.	0.5	133
33	Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10119-E10126.	3.3	180
34	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). , 2018, 6, 75.		188
35	Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3001-3001.	0.8	16
36	Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3071-3071.	0.8	3

#	ARTICLE	IF	CITATIONS
37	Neoadjuvant atezolizumab + chemotherapy in resectable non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2018, 36, 8532-8532.	0.8	26
38	A comparative safety analysis for durvalumab in patients with locally advanced, unresectable NSCLC: PACIFIC versus pooled durvalumab monotherapy studies.. Journal of Clinical Oncology, 2018, 36, 8556-8556.	0.8	1
39	Durvalumab in 3rd-line advanced NSCLC: Updated results from the phase 2 ATLANTIC study.. Journal of Clinical Oncology, 2018, 36, 9058-9058.	0.8	3
40	Treatment outcomes of cutaneous adverse events to immune checkpoint inhibitors.. Journal of Clinical Oncology, 2018, 36, e22093-e22093.	0.8	3
41	An open-label, multidrug, biomarker-directed, multicentre phase II umbrella study in patients with non-small cell lung cancer, who progressed on an anti-PD-1/PD-L1 containing therapy (HUDSON).. Journal of Clinical Oncology, 2018, 36, TPS3120-TPS3120.	0.8	6
42	MORPHEUS: A phase Ib/II multi-trial platform evaluating the safety and efficacy of cancer immunotherapy (CIT)-based combinations in patients (pts) with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2018, 36, TPS9105-TPS9105.	0.8	6
43	Characteristics and outcomes of Latino patients with EGFR-mutant NSCLC.. Journal of Clinical Oncology, 2018, 36, e13578-e13578.	0.8	0
44	Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncology, The, 2017, 18, 31-41.	5.1	845
45	A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature, 2017, 551, 517-520.	13.7	532
46	Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. Clinical Lung Cancer, 2017, 18, 34-42.e2.	1.1	29
47	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). Journal of Clinical Oncology, 2017, 35, 2781-2789.	0.8	348
48	Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients.. Journal of Clinical Oncology, 2017, 35, 3007-3007.	0.8	15
49	Association of liver metastases (LM) with survival in NSCLC patients treated with durvalumab (D) in two independent clinical trials.. Journal of Clinical Oncology, 2017, 35, 3038-3038.	0.8	8
50	Clinical outcomes of patients with non-small cell lung cancer (NSCLC) receiving chemotherapy after immune checkpoint blockade.. Journal of Clinical Oncology, 2017, 35, 9082-9082.	0.8	35
51	A phase 1 study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of the OX40 agonist MEDI0562 in combination with tremelimumab or durvalumab in adult subjects with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, TPS3100-TPS3100.	0.8	3
52	PROCLAIM-001: A first-in-human trial to assess tolerability of the protease-activatable anti-PD-L1 Probody CX-072 in solid tumors and lymphomas.. Journal of Clinical Oncology, 2017, 35, TPS3107-TPS3107.	0.8	2
53	The use of immunotherapy in the first-line treatment of lung cancer. Clinical Advances in Hematology and Oncology, 2017, 15, 190-192.	0.3	1
54	Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 2969-2979.	0.8	397

#	ARTICLE	IF	CITATIONS
55	Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 2980-2987.	0.8	444
56	Into the Clinic With Nivolumab and Pembrolizumab. Oncologist, 2016, 21, 527-528.	1.9	17
57	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA - Journal of the American Medical Association, 2016, 315, 1600.	3.8	857
58	PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?. , 2016, 4, 48.		178
59	Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncology, The, 2016, 17, 299-308.	5.1	556
60	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science, 2016, 351, 1463-1469.	6.0	2,445
61	PD-L1 expression in advanced NSCLC: Primary lesions versus metastatic sites and impact of sample age.. Journal of Clinical Oncology, 2016, 34, 3025-3025.	0.8	18
62	A phase 1 study of enoblituzumab in combination with pembrolizumab in patients with advanced B7-H3-expressing cancers.. Journal of Clinical Oncology, 2016, 34, TPS3104-TPS3104.	0.8	16
63	Immunotherapy for Advanced Lung Cancer. Cancer Journal (Sudbury, Mass), 2015, 21, 383-391.	1.0	10
64	Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncology, The, 2015, 16, 257-265.	5.1	1,269
65	Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 372, 2018-2028.	13.9	5,183
66	Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science, 2015, 348, 124-128.	6.0	6,756
67	Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558,) Tj ETQq1 1 0.784314 rgB Clinical Oncology, 2015, 33, 2004-2012.	0.8	1,035
68	Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers. Clinical Lung Cancer, 2015, 16, 514-522.	1.1	10
69	Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC.. Journal of Clinical Oncology, 2015, 33, 3014-3014.	0.8	25
70	Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A.. Journal of Clinical Oncology, 2015, 33, 3015-3015.	0.8	9
71	Defining the immunologic phenotype of thymic epithelial tumors.. Journal of Clinical Oncology, 2015, 33, 7516-7516.	0.8	3
72	Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers.. Journal of Clinical Oncology, 2015, 33, 8007-8007.	0.8	15

#	ARTICLE	IF	CITATIONS
73	Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1â€“positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001.. Journal of Clinical Oncology, 2015, 33, 8026-8026.	0.8	12
74	Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1â€“selected patients with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 8028-8028.	0.8	44
75	Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 8032-8032.	0.8	97
76	Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2014, 32, 8007-8007.	0.8	32
77	Nivolumab plus Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2013, 369, 122-133.	13.9	3,776
78	Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Nonâ€“Small-Cell Lung Cancers. Journal of Thoracic Oncology, 2013, 8, 1084-1090.	0.5	111
79	Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel As Initial Chemotherapy in Patients With Stage IV Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2008, 26, 639-643.	0.8	122